Join BIOCYTOGEN at World ADC San Diego 2024
We are thrilled to announce our participation as an exhibitor at World ADC San Diego 2024, the world’s largest and most comprehensive conference dedicated to antibody-drug conjugates. Taking place from November 4th to 7th in San Diego, this premier event brings together leading experts and innovators to exchange ideas, gain insights, and drive new advancements. We look forward to an exciting convergence of innovation, collaboration, and inspiration, as we work to elevate ADC development and transform standards of care in oncology and beyond.
What is World ADC San Diego 2024?
This event offers an unparalleled experience for everyone involved with ADCs, from newcomers to seasoned key opinion leaders. Tailored to meet the specific needs of the industry, this year’s program has been reinvigorated with fresh insights from over 140 leading speakers. Over the course of four days, attendees will explore cutting-edge advancements in linker-payload design, evaluate novel targets, and accelerate both preclinical and clinical development while addressing the challenges of toxicity. It promises to be a transformative gathering for those driving the future of ADCs.
Event Overview
Date: November 4th 8:00 am – 7th 6:00 pm
Venue: Town & Country San Diego, 500 Hotel Circle North, San Diego, CA 92108, USA
Event Schedule
The World ADC San Diego 2024 in Houston will showcase a diverse array of speakers and topics. For a comprehensive look at the daily schedule, including session times and detailed information on each presentation, please refer to the World ADC San Diego 2024 agenda.
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We look forward to seeing you at the World ADC San Diego 2024 in San Diego!
